Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding

Feb 11 2013

• By Brenda Sandburg

Related Content

Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers

Feb 07 2013

Track-And-Trace Will Not Hitch A Ride On The User Fee Train

Jun 18 2012

Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data

Dec 12 2012

Track and Trace Standards Coming Shortly, FDA Says

Jan 02 2012

FDAAA Impact Analysis (Year 4): The REMS Retreat Continues - For Now

May 29 2012

FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs

Mar 07 2012

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

Feb 13 2012

Drug Sample Distribution Reporting Deadline Extended By FDA

Apr 09 2012

Biosimilar User Fee Meeting Schedule Allows FDA Data “Pre-Review”

Sep 17 2012

Rare Disease Improvements Planned Soon, And Up To Five Years From Now

Feb 07 2011

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window